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ABSTRACT
Background: The extent to which patient-based out-
comes can be used to evaluate and communicate the effect
of new drugs and devices is a subject of much debate.
Criteria for evaluating the scientiﬁc quality of data to
support health-related quality of life (HRQL) and other
patient-based labeling and promotional claims in the
United States and Europe have been proposed by various
scientists and organizations. Since March 2000, a work-
ing group composed of members of the International
Society for Quality of Life Research (ISOQOL), the Inter-
national Society for Pharmacoeconomics and Outcomes
Research (ISPOR), the Pharmaceutical Manufacturer’s
Association Health Outcomes Committee (PhRMA-
HOC), and the European Regulatory Issues on Quality of
Life Assessment (ERIQA) met to discuss and coordinate
the various recommendations by their respective groups
and address the need to harmonize outcomes review cri-
teria within and across United States and European
regulatory agencies. Over time, the discussion expanded
from HRQL outcomes to include any outcome based on
data provided by the patient or patient proxy, that is,
patient-reported outcomes (PROs). The working group
therefore became known as the PRO Harmonization
Group.
Methods: Working with a member of the US Food and
Drug Administration (FDA), four key issues requiring
clariﬁcation were identiﬁed: how PROs are deﬁned and
put into operation for research purposes; the added value
of PROs in the drug review and evaluation process;
selected questions related to the PRO measurement and
research methodology; and the interest and demand for
PRO information by decision makers. On February 15,
2001, all members of the PRO Harmonization Group
attended a meeting in Rockville, Maryland, to discuss
these four issues further, and on February 16, 2001, a for-
mal presentation was made to representatives from vari-
ous departments and reviewing divisions of the FDA.
These presentations are summarized in this report.
Results: All participants agreed that PROs are important
for understanding the impact of treatment on patient
functioning and well-being. They also stressed the need to
communicate PRO information to key decision makers,
including regulatory agencies, clinicians, patients and
their families, and payers. Finally, the meeting resulted in
plans for continuing the dialogue on PRO measurement
and interpretation.
Summary: The February 16, 2001, meeting represented
an important step in harmonizing efforts across various
organizations and in opening a dialogue with the FDA
around major issues related to methodologic standards
for measuring and interpreting PROs in the drug evalua-
tion process.
Keywords: claims, health-related quality of life (HRQL),
patient-reported outcomes (PRO), regulatory issues.
Introduction
Health-related quality of life (HRQL) and other
patient-based assessments are important for under-
standing the impact of treatment on patient func-
tioning and well-being [1,2]. The extent to which
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these outcomes can be used to evaluate and com-
municate the effect of new drugs and devices is
a subject of much debate. In the United States, a
number of products have been reviewed at the US
Food and Drug Administration (FDA) for approval
to communicate HRQL outcomes in labeling and
promotion. Along with these submissions have
come questions about the underlying methodology
of HRQL research and its application to the drug
approval process.
To address the need for additional information,
criteria for evaluating the scientiﬁc quality of data
to support HRQL labeling and promotional claims
in the United States have been proposed by inde-
pendent scientists [3] and organizations, including
International Society for Quality of Life Research
(ISOQOL) [4] and the International Society for
Pharmacoeconomics and Outcomes Research
(ISPOR) (http://www.ispor.org), with ongoing
discussions by the Pharmaceutical Research and
Manufacturer’s Association Health Outcomes
Committee (PhRMA-HOC) [5]. At the same time,
the European Regulatory Issues on Quality of Life
Assessment (ERIQA) group assessed the use of
HRQL outcomes in regulatory reviews conducted
in Europe [6].
In an effort to coordinate the various recommen-
dations provided by these groups and to formulate
principles to guide HRQL outcomes review criteria
within and across regulatory agencies in the United
States and Europe, a working group of members
from the four organizations was convened. Over
time, the discussion expanded from HRQL out-
comes to include any outcome based on data pro-
vided by patients or patient proxy as opposed to
data provided from other sources (Fig. 1). The FDA
proposed the term “patient-reported outcomes”
(PRO) to represent these types of outcomes in the
regulatory review process [7]. The working group
subsequently became known as the PRO Harmoni-
zation Group.
Based on the results of previous discussions and
input from the FDA, the PRO Harmonization
Group identiﬁed and focused on four key issues
requiring clariﬁcation within the context of drug
evaluation: 1) the deﬁnition and operation of PROs
for research purposes; 2) the added value of PROs
in the drug review and evaluation process; 3) spe-
ciﬁc questions related to the PRO methodology; and
4) interest and demand for PRO information by
decision makers. Participants from the four groups
were divided into task groups to address each of the
issues identiﬁed above and to make recommenda-
tions to the PRO Harmonization Group. After sub-
stantial deliberations, the PRO Harmonization
Group presented results and recommendations on
these four issues to the FDA on February 16, 2001.
Objectives and Scope
The objective of the meeting was to open a dialogue
between the FDA and organizations interested and/
or engaged in PRO research. Four presentations
were made: 1) PRO Concept and Deﬁnition, Team
Leader, Margaret Rothman, PhD; 2) Value of PROs,
Team Leader, Nancy Kline Leidy, PhD; 3) Method-
ological Considerations for PRO Data in Clinical
Trials, Team Leader, Patrick Marquis, MD; and 4)
Interest in and Demand for PRO Information, Team
Leader, Rick Berzon, DrPH. The contents of these
presentations are summarized in this report.
Concept and Deﬁnition of PRO
Group 1 presented a framework for and a concep-
tual deﬁnition of HRQL and PROs. Deﬁnitional
clarity is important to any scientiﬁc endeavor. Lack
of clarity around deﬁnitions related to PROs, espe-
cially HRQL, impedes development of the ﬁeld,
hampers communication with patients and clini-
cians, and hinders discussion and policy develop-
ment. Whereas it is generally agreed that HRQL is
an important concept, there is no universally agreed
upon deﬁnition or clearly developed conceptual
framework for understanding the relationship
between HRQL and PROs.
One approach to categorizing data collected in
clinical trials is to consider the source of informa-
tion. There are several potential sources of data to
evaluate the safety and efﬁcacy of a new drug
(Fig. 1), i.e., patients, clinicians, and caregivers.
Each source shown in Fig. 1 serves as an umbrella
term for the types of data that may be provided by
that source. It is generally acknowledged that each
source may provide a unique and valuable perspec-
tive on the disease and the efﬁcacy of a therapy. For
example, patients may focus on the changes in their
own health; families may react not only to the
impact on the patients, but also to the impact on
family life; and clinicians and researchers view dis-
ease and its treatment from a clinical perspective.
The proposed framework and deﬁnition are
based on two guiding principles. First, PRO assess-
ment, especially in the context of drug evaluation, is
an evolving ﬁeld. Any proposed framework and def-
inition should be broad rather than prescriptive,
thus fostering rather than hindering the growth of
the ﬁeld. Second, the framework and deﬁnition are
proposed for use within the context of the drug
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approval and regulatory process. Appropriateness
for use beyond this context must be evaluated
separately.
Initial discussion began with a delineation of
those issues on which there appeared to be broad
general agreement including the information pro-
vided by the patient is inherently subjective; the
patient’s subjective experience provides a unique
and valuable contribution to the drug development
process; scientiﬁc methods for assessing subjective
outcomes, e.g., psychometrics and utility measure-
ment, are well developed and provide the basis for
PRO assessment; the design of PRO studies follows
the rules deﬁned for clinical trials, e.g., clear speci-
ﬁcation of hypotheses and standard methods of
analysis and interpretation; and the HRQL repre-
sents the patient’s report of the impact of a health
condition, varies by disease or health condition
and over time, consists of multiple domains, and
includes the concept of the value placed on the
assessed outcome.
HRQL is one of several types of PRO data that
may be collected in the context of a clinical trial.
Other PROs include, but are not limited to, symp-
toms, patient satisfaction with treatment, functional
status, psychological well-being, and treatment
adherence (Fig. 1). The following deﬁnitions
evolved: patient-reported outcomes represent the
patient’s report of a health condition and its treat-
ment, and HRQL represents the patient’s evaluation
of the impact of a health condition and its treatment
on daily life.
Patient’s evaluation implies that the patient is the
preferred respondent for HRQL data. It is recog-
nized that at the present time, not all patients can
provide such information, e.g., very young children
and persons with severe dementia. Information pro-
vided by other sources, generally referred to as
proxy or surrogate respondents, is not equivalent
to that which would be provided by the patient.
Research ﬁndings suggest that the degree of associ-
ation between patient and proxy data varies accord-
ing to the extent to which a behavior is observable.
In those cases where the behavior is unobservable,
data may be biased by characteristics of the proxy
respondent [2,8].
Impact on daily life implies that the domains
assessed are relevant to the patient and indicates
that the assessment goes beyond mere counting of
events. For example, the number of times a patient
reports an episode of heartburn, or symptom fre-
quency, over a deﬁned period of time does not pro-
vide an evaluation of the impact of heartburn on the
patient’s daily life and, hence, can only be consid-
ered a symptom inventory, but not a domain of
an HRQL instrument. In contrast, an assessment of
heartburn-related symptom distress experienced by
the patient does provide an impact component and
thus may represent a HRQL domain. Research sug-
gests that frequency and distress evaluations may
yield different information; thus the impact compo-
nent provides unique information [9,10].
The notion of multidimensionality is a key com-
ponent of deﬁnitions of HRQL. A single domain,
e.g., physical function, cannot be considered as a
HRQL measure, even though it is a patient-reported
outcome. The type and number of domains required
for an HRQL instrument are not speciﬁed in this
deﬁnition as the group, and the committee as a
whole by its adoption of the deﬁnition believed that
this varies by health condition and treatment. It is
incumbent on the researcher or sponsor to provide
evidence that sufﬁcient coverage of domains rele-
vant to the target population are included in the
assessment to uphold a HRQL claim.
The group did not speciﬁcally endorse any of the
paradigms that attempt to delineate the relation-
ships among types of PROs and other variables,
e.g., Wilson and Cleary [11], as there appeared to
be insufﬁcient evidence to support hypothesized
relationships. Further research into the relation-
ships among PROs is required to enhance our
understanding of illness and treatment from the
patient’s perspective.
The Value of PROs
Group 2 introduced the value of the patient’s per-
spective and structured its argumentation around
four key points: 1) a unique indicator of the impact
of disease; 2) essential for evaluating treatment efﬁ-
cacy; 3) useful for interpreting clinical outcomes;
and 4) a key element in treatment decision making.
Figure 1 Patient outcomes assessment: sources and examples.
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A unique indicator of the impact of disease.
The patient’s report of symptoms, side effects, and
other health-related data gathered during history
taking are important entries in the multifactorial
database that is the foundation for accurate medical
diagnosis and treatment. In many situations, the
physician relies almost entirely on patient reports in
evaluating disease activity. The management of con-
ditions such as functional gastrointestinal disorders,
sexual dysfunction, benign prostatic hypertrophy,
and insomnia, for example, is based almost entirely
on the patient’s report of symptoms and their
impact on daily functioning and well-being. Suc-
cessful treatment of migraine headache is deﬁned
by two patient-reported outcomes: pain relief and
return to normal daily activities. Similarly, the
optimal dose of antihistamines for the treatment
of seasonal allergic rhinitis is based on achieving
symptom relief to the point of tolerability, that is,
symptom relief with minimal side effects resulting in
optimal functioning and well-being.
There are many situations in which patient-
reported data and objective physiologic markers of
disease activity are used concomitantly to determine
the severity of disease, monitor the trajectory of
illness and select or adjust the optimal treatment
regimen. Diagnosis and treatment of chronic
obstructive pulmonary disease (COPD), for exam-
ple, include a considered evaluation of the patient’s
history of respiratory symptoms along with labora-
tory and spirometric evaluation [12,13]. The goals
of management in COPD are to: 1) reduce airﬂow
limitation; 2) prevent and treat secondary medical
complications; and 3) decrease respiratory symp-
toms and improve quality of life [12].
The historically weak empirical relationship
among pulmonary function, symptoms, and HRQL
supports the need for simultaneously considering
each of these clinical parameters in understanding
the impact of disease and treatment [14,15]. The
fact that some treatments can reduce symptoms and
improve HRQL with minimal change in FEV1 fur-
ther highlights the important and complementary
nature of subjective and objective parameters of dis-
ease activity in this population [16].
Change in the patient’s report of functional
limitations is an important, and often a primary,
clinical indicator of disease progression and treat-
ment effectiveness for chronic conditions such as
rheumatoid arthritis, Parkinson’s disease, multiple
sclerosis, stroke, and traumatic brain injury.
Although objective tests of performance, such as
muscle strength and joint function, provide data on
the patient’s functional capacity, these indicators do
not assess daily functioning in and around the home
or work setting [17,18]. Treatment guidelines pro-
vided by a number of different professional organ-
izations recommend that these data be gathered
directly from the patient. Assessing HRQL is con-
sidered part of the standard of care in the treatment
of allergy [19], COPD [12], and gastroesophageal
reﬂux disease [20] and in rheumatology [21,22]. By
deﬁnition, treatments for chronic diseases are palli-
ative rather than curative. Thus, PROs of all types,
e.g., HRQL, preference or satisfaction with treat-
ment, or health status, are appropriate indicators of
disease activity and progression.
Essential for evaluating treatment efﬁcacy.
In clinical trials, as in practice, patient report is the
sole source of data on frequency and severity of
symptoms and side effects and the impact of treat-
ment on functioning and well-being. Consistent
with the deﬁnition of a scientiﬁc instrument, PRO
measures provide precise, reliable, valid, and repro-
ducible data. The data represent the quantiﬁcation
of the patient perspective of the impact of disease
and treatment.
PROs are essential endpoints in any clinical trial
in which: 1) the patient’s self-report is the primary
or sole indicator of disease activity; 2) the treatment
has a small impact on survival but may have a sig-
niﬁcant impact, positive or negative, on HRQL; 3)
the treatment may adversely affect patient function-
ing and well-being; 4) the treatment arms offer
equal clinical efﬁcacy but differential PRO beneﬁts;
and 5) treatment-related decisions are based on a
combination of objective and patient-reported sub-
jective parameters.
Useful for interpreting clinical outcomes. PRO
data from clinical trials contribute to the compre-
hensive evaluation of the beneﬁts of new treatment.
The result of a trial examining the efﬁcacy of levei-
racetam in reducing seizure frequency in patients
with epilepsy is a case in point [23]. In this study,
the HRQL outcomes of patients categorized as
“responders,” that is, patients for whom the treat-
ment was efﬁcacious, differed across the three
treatment groups, suggesting a differential HRQL
beneﬁt of treatment distinct from the primary end
point (Fig. 2).
Results of a trial examining the efﬁcacy of riza-
triptan for the treatment of migraine is an example
of the importance of data provided by the patient in
evaluating optimal dosing regimens [24]. In this
trial, the 5- and 10-mg doses of rizatriptan were
each found to be signiﬁcantly more efﬁcacious
than placebo in relieving pain. However, patients
randomly assigned to the 10-mg group showed
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signiﬁcantly better responses on three of ﬁve
domains of HRQL assessed in the study (Fig. 3).
These additional data suggest that 10 mg is the dose
of choice for achieving pain relief sufﬁcient to
improve functioning and well-being.
A key element in treatment decision making.
A number of specialty groups and organizations
recommend the use of PROs in clinical trials and
have published guidelines for selecting outcome
measures speciﬁc to the unique characteristics
and evaluation needs of the underlying disease.
The Outcome Measures in Rheumatoid Arthritis
Clinical Trials (OMERACT) Group has recom-
mended that clinical trials include a comprehensive
appraisal of symptoms such as pain and joint stiff-
ness, and the HRQL effects of treatment [21,22].
The systemic lupus erythematosus subgroup speciﬁ-
cally recommended the inclusion of the patient-
reported measure of health status, disability, and
HRQL [21]. The Group for the Respect of Ethics
and Excellence in Science (GREES) recommenda-
tions for the registration of drugs used in the treat-
ment of rheumatoid arthritis suggests that generic
and disease-speciﬁc measures of HRQL be included
as secondary efﬁcacy end points for clinical trials
of symptom-modifying drugs [25]. In oncology,
according to Johnson and Temple, “parameters
of efﬁcacy for advanced metastatic disease are sur-
vival, quality of life (performance status or pain),
objective tumor response, and time to treatment
failure” [26].
The goal of evidence-based medicine is to
improve the quality and efﬁciency of medical care
by basing treatment on sound scientiﬁc rationale.
Any treatment designed to improve symptoms,
functioning, well-being, or other PROs should also
be based on scientiﬁc evidence, which is data from
well-controlled clinical trials. PROs of clinical trials
are particularly important for decision makers faced
with limited resources and/or confronted with the
evaluation of tradeoffs between efﬁcacy, toxicity,
and costs. Sound, scientiﬁc PRO data for any med-
ical treatment, including pharmacologic therapies,
is key to evidence-based decision making. A sum-
mary of the key points on the value of PROs is pre-
sented in Table 1.
Methodologic Considerations in Assessing PROs 
in Clinical Trials
Group 3 focused on selected methodologic issues
associated with PRO assessment. Two key aspects
were presented: the scientiﬁc value of PRO meas-
ures and the standards and procedures to follow for
assessing PROs in clinical trials. PRO measures are
scientiﬁcally valid insofar as: 1) the outcomes can be
conceptually deﬁned; 2) they can be put into oper-
ation through questionnaires; and 3) the question-
naires can be demonstrated to be reliable, valid, and
responsive [27].
PRO measures have been primarily developed
and validated based on psychometric theory
although other approaches are used, e.g., utility
[28]. Psychometrics has a long history in the human
sciences [29–31]. Current HRQL questionnaires
beneﬁt from the experience accumulated over the
past 50 years in this ﬁeld. Empiric validation sup-
ports their status as scientiﬁc measures [32]. The
validation process consists of different aspects that
are well deﬁned. The Harmonization Group
adopted standard deﬁnitions and methods for
assessing reliability, validity, and responsiveness
Figure 2 HRQL outcomes of seizure—responders by treatment
group.
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Figure 3 Efﬁcacy of rizatriptan in migraine.
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[2–6,27–32]. These measurement characteristics are
widely accepted and considered essential for assur-
ing that a PRO instrument is meaningful to patients
and clinicians and provides accurate and valid
measurements of the intended domains.
For PROs to be incorporated as evaluation crite-
ria in the drug approval process and as support for
promotional or labeling claims, they must meet
the same standards as traditional clinical mea-
sures [6,33]. More speciﬁcally, several methodo-
logic issues are important: 1) speciﬁcation of the
PRO research question and end point; 2) selection/
development and validation of PRO questionnaire;
3) study design and PRO evaluation; 4) data anal-
ysis; and 5) interpretation and reporting.
Decisions about the incorporation of a PRO
strategy into a clinical trial should be made with the
research design and intended claim in mind. It is
important to address questions such as “what is
the claim you are hoping to achieve?” and “what
are the research questions and the measures that
address that claim?” PRO research and clinical tri-
als should be driven by hypotheses, and appropriate
hypothesis testing requires attention to research
design, data collection procedures, and conduct of
the clinical trial.
The selection of the PRO measure should be jus-
tiﬁed, based on the domains of interest for the
patients, the drug proﬁle, and the hypotheses being
tested. The development of the questionnaire
should be based on patient interviews and it should
provide adequate assessment of the domains of
interest. Psychometric evidence of the question-
naire’s reliability and validity must be provided.
Ideally, responsiveness for the domains on which
the hypotheses are tested should be demonstrated
before the clinical trial.
The evaluation must follow clinical research
standards and be designed in such a way that it ade-
quately addresses the hypotheses being tested. The
study design should address any issues that might
negatively affect or compromise the integrity of
the study, such as randomization, mode and timing
of questionnaire administration, and prevention of
missing data. Each of these research design consid-
erations is linked to the target disease and patient
population under study and the effects of treatment
on the targeted disease.
The speciﬁc statistical analysis procedures must
be outlined and developed to relate to the prespec-
iﬁed hypotheses and the targeted claim, even when
the PRO is a secondary end point. A full analysis
plan must be developed a priori to include the scor-
ing method, the adjustment procedure for multiple
testing, and a scientiﬁc procedure to handle missing
data. A speciﬁcation of the data analysis strategy
and statistical models is required.
Interpretation should be made in the light of the
clinical ﬁndings and should go beyond statistical
signiﬁcance. The consistency of PRO ﬁndings with
other variables reported in the clinical trial and how
this information can supplement clinical end points
should be discussed. Full disclosure of all results
should be provided and must include compliance
with questionnaire completion, in relation to the
loss of patients to follow-up, and score distribution,
both at baseline and over time [34,35].
In conclusion, PROs are scientiﬁc measures that
can evaluate change in outcomes. They must be
handled like any other effectiveness end point in
clinical trials. Methods for selecting, developing,
validating, measuring, and reporting PROs are
similar to those for other clinical effectiveness
measures. PROs focus attention on the patient’s per-
spective because patient information is derived from
focus groups or individual interviews used to iden-
tify relevant content and domains.
Interest in and Demand for PRO Information
Group 4 was charged with reporting the reasons
driving the interest in and demand for PRO
information.
Over the past decade, a variety of demographic,
social, and technologic phenomena have been
driving the interest in and demand for PRO infor-
mation. Speciﬁc trends include an increasing
prevalence in chronic illnesses [36,37], patient
empowerment [38], and advances in information
technology [39–42].
Chronic illnesses are increasing in prevalence;
and people with these conditions are living longer
Table 1 Summary of key points on the value of PROs
• The patient’s perspective is a key element in medical diagnosis and 
treatment.
• Patient-reported data are unique and complementary indicators 
of disease activity and treatment effectiveness.
• Professional organizations recognize the key role patient-
reported data play in diagnosis and treatment, as evidenced by 
professional practice guidelines.
• PROs in clinical trials provide important data for evaluating the 
effectiveness of new treatment.
• Consistent with the deﬁnition of a scientiﬁc instrument, patient-
reported outcome measures provide precise, reliable, valid, and 
reproducible data.
• The inclusion of PROs in clinical trials is sanctioned by 
professional organizations, as evidenced by trial guidelines put 
forth by professional organizations.
• PRO data are essential for evidence-based practice.
• For new pharmaceuticals, PRO data from clinical trials support 
evidence-based practice.
Abbreviation: PROs, patient-reported outcomes.
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fuller lives. Current US census demographic data
reveal that 13% of the US population is age 65 or
older [43]. Over the next 30 years that number will
increase to 20%. According to US Census Bureau
projections [43], the largest increases in the elderly
population will be in people over the age of 85. In
1994, this group represented 10% of the elderly and
1% of the overall population; by 2050, those per-
centages are expected to rise to 24 and 5%, respec-
tively [43].
Chronic illnesses are incurable by deﬁnition;
therefore, improving patient HRQL and providing
PRO information has become a reasonable assess-
ment of a drug’s value. Improving the patients’ well-
being and ability to function are important new end
points for many chronic illnesses.
Patient empowerment is a primary driver of
demand for PRO information. The increasing inter-
est of patients and their ability to actively under-
stand, participate in, and inﬂuence their health-care
decisions has changed the traditional doctor/patient
relationship. Findings from HRQL assessments pro-
vide more complete and relevant information to
patients in ways that have intuitive value to them.
Patients gain insights and a more comprehensive
understanding of treatment risks and beneﬁts. Fur-
thermore, this information may increase patients’
participation in their own treatment and gives them
a voice in health-care decision making that, until
recent years, has been lacking.
People with chronic conditions have begun to
realize that by learning more about their illness, it is
possible to live life with a sense of continuity and
control. According to Segal [38], “. . . capacity for
self-care is central to the management of chronic
diseases . . . and health education is a central ele-
ment in the best practice protocols for the manage-
ment of these conditions.” Technologic tools, such
as the Internet, contribute to individual empower-
ment and make it easier for health-care information
to be communicated to those who are ill. Patients
can discover the strengths and weaknesses of
therapeutic regimens through use of the Internet,
HRQL, PRO data and through more traditional
means. All of these developments foster communi-
cation with health-care providers and reinforce
patients’ feelings of empowerment.
Physicians use PRO information in their discus-
sions with patients to recommend treatments that
are efﬁcacious and have minimum adverse side
effects. The addition of PRO data in labeling can
help clinicians present the value of treatment alter-
natives to patients. Patient-relevant data includes
information concerning any change in the ability,
for example, to perform activities of daily living or
instrumental activities of daily living. This informa-
tion should be as readily available as data related
to adverse events. More importantly, PRO infor-
mation increases clinician–patient communications
and encourages patients to become self-reliant.
According to one clinician [29], “. . . For centuries,
the medical profession . . . perpetrated a paternal-
ism that deprived patients of the self-esteem that
comes from self-reliance.” Today, the age-old adage
that knowledge is power has new meaning for
health-care consumers. Better clinician–patient
communications and patient empowerment have
affected the entire health-care system, encouraging
health-care businesses to provide patients with per-
tinent, patient-friendly information on their health
status. Patient information sheets provided by clini-
cians at the time of emergency room discharge
translate clinical ﬁndings into relevant information
that can be understood by patients. Translating
degree of improved lung capacity into the ability to
walk without impaired breathing is another illustra-
tion of this ideal.
In breast cancer, PRO information can inﬂuence
how patients perceive the condition and how clini-
cians treat it. Kiebert et al. [44] reviewed the breast
cancer literature and found that in mastectomy
versus breast-conserving surgery, where survival
outcomes are similar, a clinician’s treatment regimen
is dependent on the patient’s perception of speciﬁc
aspects of HRQL. Kiebert and colleagues found
that in 10 of 18 studies, patients experienced a more
positive outcome with respect to body image after
surgery with breast-conserving treatment. These
and other ﬁndings caused the authors to conclude
that the more a patient is involved in the treatment
decision-making process, the more likely it is that
surgery will be limited [44].
Epilepsy is a chronic illness with serious physical
and social consequences for patients. It is a diverse
disorder, characterized by transient disturbances of
brain function manifested as altered consciousness
or episodic impairment of function. The seizures are
often not satisfactorily controlled even after antie-
pileptic drugs are initiated [45]. In addition to the
physical aspect of the illness, the emotional and
social issues must be considered. Lack of self-
esteem, embarrassment, and a reduced ability to
perform normal social activities such as driving and
participating in sports are all pertinent HRQL
issues for subjects with this diagnosis [46]. As is the
case with breast cancer, epilepsy can demonstrate
the value of PRO data in inﬂuencing clinician-
recommended treatment regimens. Increased
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patient participation in the treatment process affects
the way therapies for the disease are mutually
selected by providers and patients and adhered to
by patients.
In conclusion, demographic, social, and tech-
nologic trends will continue to drive the interest in
and demand for PRO information. The increase
in methods of communication will continue to mod-
ify the doctor/patient relationship, empowering
patients and affecting not only the means by which
information is conveyed, but also the very nature of
the information itself. PROs, and HRQL informa-
tion in particular, will play an increasingly vital role
in these events.
Discussion
PRO measures extend patient outcome assessment
beyond survival, traditional clinical efﬁcacy, and
adverse effects and most importantly represent the
patient’s perspective on the impact of disease and its
treatment on her/his everyday functioning and well-
being. Whereas PROs have been incorporated into
clinical trials over the past 20 years, there remains
concern about the value and application of these
measurements in the evaluation of new therapies.
The focus of the PRO harmonization effort is on
addressing the application of PRO end points in the
evaluation and review of new therapies for approval
by the FDA and other regulatory agencies. The pri-
mary intent is to clarify areas of ambiguity and pro-
vide regulatory agencies with recommendations on
the best practices in PRO assessment. This effort
also identiﬁed unresolved research issues associated
with the use of PROs in evaluating new medical
treatments. There is no intent to provide overall
guidance and recommendations on the development
and use of PROs for other applications, such as
monitoring the health status of population, evalu-
ating the quality of medical services delivery, or
evaluating other health interventions.
Several other PRO research issues were raised
during the meeting held at the FDA in February
2001 including:
1. What are the scientiﬁc standards associated
with PRO instrument development?
2. What are the issues associated with PRO instru-
ment selection, including rationale and hypoth-
eses, relationships with clinical end points?
3. What is the state of the science in handling
missing data in PRO statistical analyses?
4. How can PRO results be interpreted, espe-
cially when there are inconsistencies between
outcomes?
These four issues were addressed in a PRO har-
monization meeting held in March 2002. The
results of this meeting are the focus of a forthcom-
ing article. In addition, FDA participants raised
issues related to recommendations for substantiat-
ing evidence supporting PRO labeling or promo-
tional claims and presentation of PRO results in the
product label. These issues will be addressed in a
future PRO Harmonization Group meeting.
The PRO Harmonization Group represents an
unprecedented level of communication between the
FDA and pharmaceutical and academic researchers.
It has contributed to understanding the value of the
patient perspective and the best practices for incor-
porating it into the drug evaluation process.
Clearly, more research is needed and future meet-
ings are needed to further develop understanding of
the PRO assessment in the evaluation and regula-
tory review process. While complete consensus may
not be reached on all issues, improving the under-
standing of researchers from industry, academia,
and regulatory agencies will ensure that clinical
trials will include state-of-the-art measures and
methods. In addition, identifying areas for future
research that will assist the FDA and other regula-
tory agencies in incorporating PRO end points into
their decision making is useful. The intent of con-
ducting clinical trials and reviewing treatment
effectiveness and safety data is to communicate
information about the risks and beneﬁts of new
therapies to physicians, patients, and their families
in terms that may be used to make individual
health-care decisions. PROs, including HRQL, are
an important component of this process.
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